Anti-PCP polyclonal antibody

Background: Abnormalities in prefrontal cortical and hippocampal GABAergic function are postulated to be major causes of the cognitive impairment associated with schizophrenia (CIAS). There are conflicting views on whether diminished or enhanced GABAergic activity contributes to the deficit in short-term novel object recognition (NOR) in the sub-chronic phencyclidine (scPCP) rodent model of CIAS. This study assessed the role of GABA(A) signaling in the medial prefrontal cortex (mPFC) and ventral hippocampus (vHPC) in NOR in saline (scSAL)- and scPCP-treated rats. Methods: The effects of local administration of a GABA(A) agonist (muscimol) into the vHPC or mPFC and an antagonist (bicuculline) or a GABA(A)/benzodiazepine partial agonist (bretazenil) into the vHPC on NOR in scSAL and scPCP-treated rats were determined. Results: In scSAL-treated rats, injection of muscimol into the vHPC, but not mPFC, induced a deficit in NOR. The scPCP-induced NOR deficit was significantly reversed by intra-vHPC bicuculline, while intra-vHPC bretazenil produced a non-significant trend for reversal (p = .06). scPCP treatment increased mRNA expression of GABAA gamma(2) in PFC and GABA(A) alpha(5) and GABA(A) beta(1) in the HPC. However, GABA concentration in the PFC or HPC was not altered. Conclusions: These findings indicate that the scPCP-induced NOR deficit can be rescued by reducing GABA(A) receptor stimulation in vHPC, indicating that increased vHPC GABA(A) inhibition may contribute to the scPCP-induced NOR deficit in rats. These results also indicate that excessive GABA(A) receptor signalling in the vHPC has a deleterious effect on NOR in normal rats.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.